ライフサイエンスコーパス: ovalbumin

1 (human transferrin, human serum albumin, and ovalbumin).

2 H2 responses after allergic sensitization to ovalbumin.

3 e of Galbeta(1-->4)GlcNAc ligands on chicken ovalbumin.

4 pidly after sensitization and challenge with ovalbumin.

5 ollowed by injection of 2,4,6-trinitrophenyl-ovalbumin.

6 from mice sensitized to native or aggregated ovalbumin.

7 rcutaneous challenge by the protein allergen ovalbumin.

8 airway epithelium were tolerized to inhaled ovalbumin.

9 deled in mice sensitized and challenged with ovalbumin.

10 ngth) produced a Th2-biased response against ovalbumin.

11 nternalized by dendritic cells and delivered ovalbumin.

12 ntraperitoneally toward the primary antigen, ovalbumin.

13 ild-type (WT) mice sensitized and exposed to ovalbumin.

14 etic) system and induced allergic asthma via ovalbumin.

15 d desensitization to the model food allergen ovalbumin.

16 Rats were sensitized with ovalbumin (1 mg SC), and anaphylactic shock was induced

17 ylactic shock was induced by IV injection of ovalbumin (1 mg).

18 Ovalbumin, a major allergen in egg whites, is prone to a

19 With the help of a cationic lipid, ovalbumin, a model vaccine antigen was efficiently loade

20 3beta) sequences following immunization with ovalbumin administered with complete Freund's adjuvant (

21 eally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged leukotriene C4 synthase-def

22 accurately identify a CD4 T cell response to ovalbumin against a background response to the complex m

23 als were exposed repeatedly to aspiration of ovalbumin alone or together with environmental adjuvants

24 -alum, followed by intranasal challenge with ovalbumin alone, to induce adaptive TH2 responses.

25 problem by co-encapsulating a model antigen ovalbumin along with TLR9 and STING ligands within lipos

26 model of allergic asthma was developed with ovalbumin-alum in female Cd39 wild type (Cd39(+/+) ) and

27 Mice were sensitized with intraperitoneal ovalbumin-alum, followed by intranasal challenge with ov

28 tolerance in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.

29 erformed intranasally or epicutaneously with ovalbumin and a secondary antigen, keyhole limpet hemocy

30 e adaptive allergic inflammatory response to ovalbumin and alum was unimpaired.

31 nd exposed to two separate allergic stimuli (ovalbumin and Aspergillus extract), genetic removal of M

32 Using ovalbumin and Bacillus anthracis protective antigen prot

33 of glycopeptides from fetuin, glycophorin A, ovalbumin and gp120 tryptic digests were used to build a

34 We used ovalbumin and house dust mite models of asthma.

35 ferent murine models of experimental asthma (ovalbumin and house dust mite); miRNAs deregulated in bo

36 Piperazine tips also enrich glycans from ovalbumin and human immunoglobulin G.

37 by co-expression of fluorescence-conjugated ovalbumin and IL-10.

38 Ovalbumin and immunoglobulin Y are selected as analytes

39 Susceptibility to pepsinolysis of ovalbumin and lysozyme was markedly enhanced by heating

40 LDI-MS identified proteolytic fragments from ovalbumin and lysozyme, exhibiting varied resistance to

41 Compared to ovalbumin and lysozyme, ovotransferrin was more suscepti

42 zyme were influenced by the treatment, while ovalbumin and ovomucoid were not affected.

43 variable regions) upon the immunization with ovalbumin and papain.

44 tion against the anaphylaxis associated with ovalbumin and peanut allergy and affects the epigenome o

45 This Vaccine-NP was compared to ovalbumin and poly(I:C) formulated in a similar manner (

46 The effect of the presence of ovalbumin and soy protein isolate on lipolysis and oxida

47 BALB/c mice were sensitized to ovalbumin and subsequent airway ovalbumin challenge.

48 We hypothesize that ACC is stabilized by ovalbumin and/or lysozyme or additional vesicle proteins

49 ed with multiple biocargos, such as antigen (ovalbumin) and adjuvant (Poly(I:C)).

50 responses were determined in the setting of ovalbumin- and house dust mite-induced lung inflammation

51 ngly, serpins are homologs of the well-known ovalbumin antigen and are associated with autoimmunity.

52 ) anti-OVA TCR transgenic mice sensitized to ovalbumin antigen, B cell depletion also impaired allosp

53 d standards from an Abl kinase sensor and an ovalbumin antigenic peptide were then employed to identi

54 In the present study, using ovalbumin as a model antigen adsorbed onto aluminum hydr

55 s shown by both the astringency method (with ovalbumin as a precipitant) and the tannins determinatio

56 vant-free experimental asthma protocol using ovalbumin as an allergen.

57 We showed that heat aggregation of ovalbumin as large particles enhances IgG production and

58 coding a CD8(+) T cell receptor epitope from ovalbumin, as well as a viral peptide-specific major his

59 1, 7a, 17, and 23 (10 mg/kg) protected in an ovalbumin/Aspergillus mouse asthma model, and PEG conjug

60 In the ovalbumin asthma model, Asm(-/-) animals were protected

61 yptophan depletion in myofibrillar proteins, ovalbumin, beta-lactoglobulin, soy protein and human ser

62 rates of lysozyme, cytochrome c, myoglobin, ovalbumin, bovine serum albumin, and etanercept were inv

63 High selectivity (1:1200, ovalbumin/BSA) and detection limit of 100 attomole is at

64 revealed that calcium inhibited glycation of ovalbumin by a mixed non-competitive mechanism in both d

65 A knockout mice (P < .005) and in vivo after ovalbumin challenge (P < .05), higher levels of apoptosi

66 Following ovalbumin challenge on days 40-42, CAIKKbeta mice in whi

67 termined by serum Mcpt1 ELISA in response to ovalbumin challenge.

68 ensitized to ovalbumin and subsequent airway ovalbumin challenge.

69 mulin plasmids were detected in the lungs of ovalbumin-challenged asthmatic mice up to 27days after a

70 ectrodeposition and used to conjugate the HA ovalbumin conjugate (HA-Ag).

71 Approximately 90% of initially internalized ovalbumin-conjugated micelles were retained in cells aft

72 le types was optimized to achieve ~50 mug of ovalbumin conjugation per mg of particle.

73 Ovalbumin conjugation to these different particle types

74 umin ratio, yolk index, air cell size, and S-ovalbumin content of UC were significantly the most supe

75 systemically applied (64)Cu-labeled chicken ovalbumin (cOVA)-TCR transgenic T cells into the pulmona

76 s on proteins (as caseins, whey proteins and ovalbumin) declared in the label of several sport nutrit

77 We induced ovalbumin-dependent colitis in mice that express ovalbum

78 Aggregated ovalbumin displayed lower Ig-binding and basophil-activa

79 vant (immunization) or of soluble gliadin or ovalbumin (ear challenge).

80 otein effects with bovine serum albumin, (S-)ovalbumin, egg white, whole egg, defatted egg yolk, whea

81 sters, which were mainly composed of chicken ovalbumin-encapsulated AuNCs, can recognize ricin B beca

82 ceptors are engineered to recognize a single ovalbumin epitope (OVA(457-462)).

83 In contrast, an ovalbumin epitope peptide was degraded at 8.9 +/- 0.1 zm

84 driven by adoptively transferred, traceable ovalbumin-experienced Th2 cells.

85 cific T cells specific for the model antigen ovalbumin expressed by engineered parasites.

86 cells to develop antitumor activity against ovalbumin-expressing melanoma.

87 an in vivo mouse model of nasal tolerance to ovalbumin, F. prausnitzii A2-165 enhanced ovalbumin-spec

88 g of CD103(+) dendritic cells (DCs) from the ovalbumin-fed DAF(-/-) mice showed impaired expression o

89 Aspergillus fumigatus, house dust mite, and ovalbumin) for 4 wk.

90 Whether we used peanut and/or ovalbumin from the egg white for sensitization, the alle

91 Model systems composed of ovalbumin, glucose, and anti-glycation agents (tannic ac

92 n of non-entrapped drug present) or protein (ovalbumin >90% reduction of OVA present) and organic sol

93 sing the HOD antigen (hen egg lysozyme [HEL]-ovalbumin-human transmembrane Duffy(b)) were transfused

94 irments included selective elevation in anti-ovalbumin IgE in plasma following immunization, reduced

95 after challenge of Spi2A knockout mice with ovalbumin in alum.

96 bumin-dependent colitis in mice that express ovalbumin in biliary epithelia (ASBT-OVA mice) and cross

97 crossed ASBT-OVA mice with mice that express ovalbumin in enterocytes (iFABP-OVA mice).

98 when it is aggregated as large particles to ovalbumin in its native form.

99 The immune response to intranasal ovalbumin in mice was assessed with concomitant infectio

100 Unlike oral feeding or ocular injection of ovalbumin in wild-type (WT) mice, which induced dominant

101 responses against the encapsulated antigen (ovalbumin) in mice.

102 el and a steroid-insensitive model combining ovalbumin-induced AAD with C muridarum (Cmu) respiratory

103 The pathology of ovalbumin-induced acute allergic airway inflammation aft

104 The development of ovalbumin-induced AD-like skin lesions was analysed in H

105 ay disease, and prevented the development of ovalbumin-induced airway hyperreactivity, eosinophilia,

106 e experimental models of house dust mite- or ovalbumin-induced airway inflammation and influenza A vi

107 disease and during the effector phase in the ovalbumin-induced allergic airway disease.

108 Ovalbumin-induced allergic airway inflammation was analy

109 ritis, an induced ulcerative colitis, and an ovalbumin-induced allergic conjunctivitis.

110 n-1) PSCs was studied in an in vivo model of ovalbumin-induced allergic inflammation and an in vitro

111 Similarly, during ovalbumin-induced allergic inflammation, pulmonary recru

112 Using the ovalbumin-induced allergic lung inflammation model, we f

113 nerated using passive cutaneous anaphylaxis, ovalbumin-induced asthma and arthritis models.

114 rway inflammation was assessed in vivo in an ovalbumin-induced asthma model by using invasive spirome

115 isothiocyanate contact hypersensitivity and ovalbumin-induced dermatitis as models for TH2-mediated

116 D(4) blocked LTC(4)-mediated potentiation of ovalbumin-induced eosinophilic inflammation; recruitment

117 With ovalbumin-induced inflammation, MCTR1 was most potent fo

118 As proof of principle, we conducted an ovalbumin-induced model of asthma in WT- and Asm(-/-) mi

119 Haemophilus respiratory infection-mediated, ovalbumin-induced severe, steroid-resistant allergic air

120 ytial virus respiratory tract infections and ovalbumin-induced, severe, steroid-insensitive allergic

121 These nanoparticles efficiently delivered ovalbumin into the cytosol of dendritic cells and demons

122 In this study, chicken egg white ovalbumin is used as a model for the study of fibril loo

123 knockout mice with EpCAM-deficient LCs with ovalbumin led to increased induction of type 2 Ova-speci

124 Development of oral tolerance to ovalbumin, levels of tolerogenic CD103(+) dendritic cell

125 of activation of CD8+ T cells in an in vitro ovalbumin model and illustrated that acid-labile polymer

126 The setup is tested with the protein ovalbumin (MW approximately 44.3 kDa) and its clusters u

127 Finally, analysis of ovalbumin N-glycans from different sources showed that t

128 control vs sensitized and/or challenged with ovalbumin, n=3-5/group) 6 hour, 24 hour, and 48 hour aft

129 etween heat-induced aggregates of ovalbumin (ovalbumin nanoparticles, OVAn) and linoleic acid (LA) we

130 icity, and therapeutic efficacy of laminarin-ovalbumin neoglycoconjugates (LamOVA).

131 wed by five oral dosing with purified AHC or ovalbumin on alternate days and continued on HFD for ano

132 estinal motility, transgenic mice expressing ovalbumin on enteric neurons were generated.

133 In models of allergic asthma using ovalbumin or cockroach allergen, mice were treated with

134 this murine model was exposed to allergens (ovalbumin or house dust mite extract) to decipher in viv

135 RAs) and assessed their abilities to reverse ovalbumin or peanut allergies in mouse models, as well a

136 C-RAs to half-maximally sensitized mice with ovalbumin or peanut allergy reduced anaphylactic respons

137 ols for food allergy induction, using either ovalbumin or peanut extract as allergens for sensitizati

138 ction when it was in formulation with either ovalbumin or recombinant hemagglutinin B (rHagB) antigen

139 fluenza and, once recovered, subjected to an ovalbumin- or house dust mite-induced experimental asthm

140 lly block nociceptors, substantially reduced ovalbumin- or house-dust-mite-induced airway inflammatio

141 I cells and cognate peptide stimulation with ovalbumin (OVA) 323-339 plus the inflammatory adjuvant,

142 ittermates were sensitized and challenged to ovalbumin (OVA) 7 or 11 times.

143 exacerbated juvenile airway disease using an ovalbumin (OVA) allergy model of asthma.

144 Furthermore, NPs co-loaded with ovalbumin (OVA) and a molecular adjuvant, monophosphoryl

145 aneously or immunized intraperitoneally with ovalbumin (OVA) and challenged intranasally with antigen

146 Female Balb/c mice were sensitized to ovalbumin (OVA) and challenged with an OVA-aerosol on tw

147 SIGIRR(-/-) C57BL/6 mice were sensitized to ovalbumin (OVA) and challenged with OVA aerosol to induc

148 -deficient (miR-155(-/-) ) mice were used in ovalbumin (OVA) and house dust mite (HDM) models of AAI.

149 xpression and activity were evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine models.

150 We employed acute ovalbumin (OVA) and house dust mite (HDM) sensitization

151 dine or activated using dimaprit in both the ovalbumin (OVA) and house dust mite extract (HDM) murine

152 mmation was induced through sensitization to ovalbumin (OVA) and repeated airway OVA challenge.

153 icroencapsulated via complex coacervation of ovalbumin (OVA) and sodium alginate (AL), and the microc

154 sh) mice were epicutaneously sensitized with ovalbumin (OVA) and then challenged orally with OVA.

155 eceptor alpha(-/-) mice were sensitized with ovalbumin (OVA) and then infected with M pneumoniae or S

156 A model antigen ovalbumin (OVA) and TLR agonists imiquimod and monophosp

157 First, ovalbumin (OVA) antigen-specific cytotoxic T-cells (CTLs

158 ization was attempted by repeated intranasal ovalbumin (OVA) applications in Naive mice.

159 We developed CH-NPs encapsulating ovalbumin (OVA) as a model antigen and poly I:C as the a

160 Using ovalbumin (OVA) as a model antigen, LSs formulated with

161 evidence in a transgenic mouse system using ovalbumin (OVA) as a model surrogate TRA that the de nov

162 We showed that an ovalbumin (OVA) asthma protocol presented a significant

163 ose on anaphylactic symptoms induced by oral ovalbumin (OVA) challenge in sensitized mice were invest

164 lavage (BAL) simultaneously, 6 h after each ovalbumin (OVA) challenge.

165 ng a heterologous CD4(+) T cell epitope from ovalbumin (OVA) consisting of OVA residues 323 to 339 (O

166 e epicutaneously sensitized female mice with ovalbumin (OVA) followed by epicutaneous sensitization a

167 B/c mice were sensitized and challenged with ovalbumin (OVA) followed with fasudil treatment.

168 re intratracheally challenged with PM2.5 +/- ovalbumin (OVA) four times at 2-week intervals.

169 6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exp

170 04, on allergic lung inflammation induced by ovalbumin (OVA) in mice and by house dust mite (HDM) in

171 allergic inflammation induced by chicken egg ovalbumin (OVA) in mice.

172 tes uptake and processing of soluble antigen ovalbumin (Ova) in primary human macrophages and dendrit

173 Balb/C mice were first sensitized with ovalbumin (OVA) in the presence of alum.

174 Oral administration of ovalbumin (OVA) in Was(-/-) mice induced low titers of O

175 In addition, immunization with ovalbumin (OVA) induced OVA-specific B cells only in hum

176 type (WT) and B cell-deficient mice received ovalbumin (OVA) intranasally before mating.

177 fractionally coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyv

178 c T cell receptor (TCR) with specificity for ovalbumin (OVA) on CD4(+)-T cells and cMy-mOVA mice expr

179 Mice were sensitized and challenged with ovalbumin (OVA) or cockroach extract (CE).

180 to wild-type recipient mice, challenged with ovalbumin (OVA) or house dust mite (HDM), and accessed f

181 spheres bound and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1.

182 C3H/HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated w

183 e that received an irrelevant immunodominant ovalbumin (OVA) peptide, OVA323-339, mice that received

184 iAD and extrinsic AD, eAD), and established ovalbumin (OVA) percutaneous sensitized AD model and pas

185 rformed by applying a skin patch soaked with ovalbumin (OVA) plus CpG, and its suppressor activity wa

186 03, and (2) induced by epicutaneous allergen ovalbumin (OVA) sensitization.

187 oli BL21 and E coli BL21_HTW were gavaged to ovalbumin (OVA) sensitized and challenged mice to invest

188 In utero injection of adjuvant-free ovalbumin (OVA) was conducted in Gestational Day 14 FVB/

189 The model allergen ovalbumin (OVA) was nitrated in different nitration degr

190 An asthma model of ovalbumin (OVA) was used in MUC1 KO and WT C57BL/6 mice

191 y, amyloids assembled from the model protein ovalbumin (OVA) were found to release the precursor prot

192 We show that the modification of Ovalbumin (OVA) with the glycan-structure Lewis(X) (Le(X

193 their physical properties then conjugated to ovalbumin (OVA), a model antigen.

194 N microparticles co-loaded with the antigen, ovalbumin (OVA), and adjuvant, CpG 1826, (PNSN(OVA + CpG

195 /-) mice were sensitized and challenged with ovalbumin (OVA), and the development of AAD was ascertai

196 Pregnant rats were sensitized to ovalbumin (OVA), bred, and challenged intranasally with

197 uce allergic responses to a second allergen, ovalbumin (OVA), in mice sensitized dually to OVA and Fe

198 a foreign, crosslinked protein, chicken egg ovalbumin (OVA), in the absence of an external adjuvant.

199 When pulsed with ovalbumin (OVA), the E. faecalis-induced DCs showed redu

200 ) was used to produce exosomes together with ovalbumin (OVA), the resulting Dexo vaccine strongly sti

201 the dose and penetration of a model vaccine, Ovalbumin (OVA), to depths of 500mum into porcine skin.

202 Using a murine model of AD induced by ovalbumin (OVA), we investigated Th2 immune responses, M

203 Cell culture and ovalbumin (OVA)- or house dust mite-based murine asthma

204 Egg white (EW)-, ovalbumin (OVA)-, and ovomucoid (OVM)-specific levels of

205 XCL1 (KC) expression were also determined in ovalbumin (OVA)-challenged wild-type female recipient mi

206 Pulmonary immunization with ovalbumin (OVA)-conjugated cationic NPs led to enhanced

207 In ovalbumin (OVA)-expressing E.G-7 tumor-bearing immune-de

208 to T and B cell responses of unimmunized and ovalbumin (OVA)-immunized BALB/c mice, and furthermore,

209 taneous preventive allergy treatment against ovalbumin (Ova)-induced airway allergy in mice.

210 s was assessed in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AA

211 Development of acute and chronic ovalbumin (OVA)-induced allergic asthma was assessed wee

212 to determine the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murin

213 We assessed the impact of ovalbumin (OVA)-induced allergic inflammation on the app

214 nt susceptibility to pneumococcal infection, ovalbumin (OVA)-induced allergic lung inflammation (ALI)

215 Here we report that AQP3 potentiates ovalbumin (OVA)-induced murine asthma by mediating both

216 itro as well as in vivo in a murine model of ovalbumin (OVA)-induced systemic tolerance.

217 Antibody suppression by ovalbumin (OVA)-primed monoclonal OVA-specific t-cell re

218 Naive and ovalbumin (OVA)-sensitized and challenged C57BL/6 wild-t

219 erived DCs (BMDCs) on airway inflammation in ovalbumin (OVA)-sensitized asthmatic mice.

220 Control and ovalbumin (OVA)-sensitized BALB/cJ mice were exposed via

221 Ovalbumin (OVA)-sensitized C57BL/6 mice were exposed to

222 Mice were then ovalbumin (OVA)-sensitized during the acute infection (3

223 Ovalbumin (OVA)-sensitized mice were desensitized to OVA

224 he draining lymph nodes of tape-stripped and ovalbumin (OVA)-sensitized skin were examined for their

225 The phenotype of circulating, ovalbumin (OVA)-specific T cells also was examined in HE

226 Ovalbumin (OVA)-specific, staphylococcal enterotoxin A (

227 B/c mice were sensitized and challenged with ovalbumin (OVA).

228 -) ) and wild-type mice were sensitized with ovalbumin (OVA).

229 of the muc5ac transcript in mice exposed to ovalbumin (OVA).

230 srupted, were sensitized and gavage fed with ovalbumin (OVA).

231 d BDNF signaling were chronically exposed to ovalbumin (OVA).

232 in WT and FHL2-knock out (FHL2-KO) mice with ovalbumin (OVA).

233 oral tolerance to a bystander food allergen, ovalbumin (OVA).

234 duction of a type 2 inflammatory reaction to ovalbumin (OVA).

235 o-mid mass proteins (Trypsin Inhibitor (TI); Ovalbumin (OVA); Bovine Serum Albumin (BSA)), we observe

236 CAF09 and a surface-adsorbed model antigen [ovalbumin (OVA)] showed that a significantly larger frac

237 ntracellular uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like

238 were then tested in an epicutaneous protein (ovalbumin, Ova) sensitization model.

239 formation between heat-induced aggregates of ovalbumin (ovalbumin nanoparticles, OVAn) and linoleic a

240 ntioxidant peptides, which were derived from ovalbumin, ovotransferrin and cystatin were isolated fro

241 nant MPO peptide (MPO(409-428)) or a control ovalbumin peptide (OVA(323-339)) to splenocytes and indu

242 We found that the ovalbumin phase-separates into core-shell particles with

243 O4@Al2O3 MNPs are functionalized with pigeon ovalbumin (POA), which contains Gal-alpha(1-->4)-Gal-bet

244 ctron tomography to measure the structure of ovalbumin precipitate particles salted out with ammonium

245 fic antibodies and enhanced proliferation of ovalbumin-reactive T cells associated with increased acc

246 Conjugation of laminarin to ovalbumin reduced its IgE binding capacity fivefold and

247 Sensitization and challenge with ovalbumin reproduced hallmark features of asthma.

248 In contrast, ovalbumin responsive T cells from OT-I mice did not exhi

249 n and challenge of mIgE-ITT-mutant mice with ovalbumin resulted in diminished serum IgE titers and re

250 S analysis of N-linked glycans released from ovalbumin revealed that several mobility features previo

251 This study compares ovalbumin's allergenicity when it is aggregated as large

252 nanostructures comprised of crystallites of ovalbumin self-assemble into a well-defined bicontinuous

253 ype (WT) and EP2(-/-) mice were subjected to ovalbumin sensitization and acute airway challenge.

254 The mouse asthma model was made by ovalbumin sensitization and challenge.

255 BALB/c mice without and with ovalbumin sensitization/challenge were infected with can

256 ecifically blocks cellular ADAM8 activity in ovalbumin-sensitized and challenged Balb/c mice.

257 ex vivo, were intratracheally injected into ovalbumin-sensitized and ovalbumin aerosol-challenged le

258 ent of airway epithelial barrier function in ovalbumin-sensitized control and prenatally stressed off

259 of lungs from prenatally stressed, non-BMC, ovalbumin-sensitized females unveiled a deregulated expr

260 sed in the skin of cathelicidin knockout and ovalbumin-sensitized filaggrin mutant mice.

261 ASMCs of asthmatic patients and in lungs of ovalbumin-sensitized mice.

262 ay smooth muscle from asthmatic patients and ovalbumin-sensitized mice.

263 on symptomatology and immune responses in an ovalbumin-sensitized mouse model of food allergy.

264 involved in asthmatic-like attacks using the ovalbumin-sensitized murine model of the disease, and id

265 Studies in mice using the model antigen Ovalbumin, showed that both combinations enhanced lymph

266 se, cholangitis developed in mice expressing ovalbumin simultaneously in biliary epithelia and entero

267 At low concentrations, ovalbumin-sized nanoparticles reach the primary filtrate

268 2 but significantly less IL-10 production by ovalbumin-specific CD4(+) T cells, resulting in prolifer

269 H4R(-/-) mice had a reduced amount of ovalbumin-specific IgE, a reduced number of splenocytes

270 A) showed significant enhancement in antigen ovalbumin-specific immunoglobulin responses compared to

271 In these mice, adoptive transfer of ovalbumin-specific OT-I CD8 T cells induced severe enter

272 months of age also had reduced frequency of ovalbumin-specific regulatory B cells compared to egg-to

273 Ovalbumin-specific regulatory B cells were identified by

274 Specific, age-dependent expansion of ovalbumin-specific regulatory T cells was only observed

275 e analyzed by flow cytometry for presence of ovalbumin-specific regulatory T cells, using activation

276 nce to egg were associated with expansion of ovalbumin-specific T and B regulatory cells, which may b

277 to ovalbumin, F. prausnitzii A2-165 enhanced ovalbumin-specific T cell proliferation and reduced the

278 rausnitzii A2-165 stimulated BMDCs increased ovalbumin-specific T cell proliferation and reduced the

279 s examined by assessment of proliferation of ovalbumin-specific T cells in rat insulin promoter-membr

280 Adoptive transfer of ovalbumin-specific TH2 and TH9 cells was used to assess

281 by co-cultures of DCs from infected mice and ovalbumin-specific, MHC class II-restricted alpha/beta (

282 In vitro ovalbumin-stimulated PBMC were analyzed by flow cytometr

283 This work illustrates the links between ovalbumin structure after heating and allergenicity pote

284 The influence of ovalbumin structure on Ig production upon sensitization

285 d tolerance induced by inhalation of soluble ovalbumin, suppressing the normal generation of forkhead

286 Conjugation of ovalbumin to laminarin increased its immunogenicity whil

287 cells in rat insulin promoter-membrane-bound ovalbumin transgenic mice after sham or IRI procedures.

288 In contrast, rejection of ovalbumin transgenic skin grafts in TORC2(DC-/-) recipie

289 the present work, we determined that murine ovalbumin-transgenic (OT-1) CD8(+) T cells recognize the

290 ia hepatic nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor I/II.

291 n partially through up-regulation of chicken ovalbumin upstream promoter transcription factor II (COU

292 ale mouse embryos lacking Coup-tfII (chicken ovalbumin upstream promoter transcription factor II) in

293 Transcription factor CTIP2 (chicken ovalbumin upstream promoter transcription factor-interac

294 Chicken ovalbumin upstream promoter-transcription factor II (COU

295 Here, we have identified chicken ovalbumin upstream promoter-transcription factor II (COU

296 lated by an orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor II (COU

297 reduction in murine response to experimental ovalbumin vaccination.

298 Ovalbumin was used as a model antigen.

299 nulation capacities of native and aggregated ovalbumin were measured with sera from egg-allergic chil

300 .1 tumor model that expresses the immunogen, ovalbumin (YOVAL1.1).